Working...
ClinicalTrials.gov
ClinicalTrials.gov Menu

TRIple in Asthma hiGh strenGth vErsus Ics/Laba hs and tiotRopium (TRIGGER) (TRIGGER)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT02676089
Recruitment Status : Completed
First Posted : February 8, 2016
Last Update Posted : July 18, 2018
Sponsor:
Information provided by (Responsible Party):
Chiesi Farmaceutici S.p.A.

Brief Summary:
The purpose of this study is to evaluate the superiority of CHF 5993 200/6/12.5 µg pMDI (fixed combination of extrafine beclometasone dipropionate plus formoterol fumarate plus glycopyrronium bromide) versus CHF 1535 200/6 µg pMDI (fixed combination of extrafine beclometasone dipropionate plus formoterol fumarate) and to compare the effect of CHF 5993 200/6/12.5 µg pMDI vs CHF 5993 200/6/12.5 µg plus open-label Tiotropium 2.5µg, in terms of lung functions parameters and rate of exacerbations, as well as to assess its safety and some health economics outcomes.

Condition or disease Intervention/treatment Phase
Asthma Drug: CHF 5993 200/6/12.5 µg Drug: CHF 1535 200/6 µg Drug: CHF 1535 200/6 µg + Tiotropium Respimat 2.5 µg Phase 3

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 1433 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: A 52 WEEK, RANDOMIZED, DOUBLE BLIND, MULTINATIONAL, MULTICENTRE, ACTIVE CONTROLLED, 3-ARM PARALLEL GROUP TRIAL COMPARING CHF 5993 200/6/12.5 µg pMDI (FIXED COMBINATION OF EXTRAFINE BECLOMETASONE DIPROPIONATE PLUS FORMOTEROL FUMARATE PLUS GLYCOPYRRONIUM BROMIDE) TO CHF 1535 200/6 µg pMDI (FIXED COMBINATION OF EXTRAFINE BECLOMETHASONE DIPROPIONATE PLUS FORMOTEROL FUMARATE) ALONE OR ON TOP OF OPEN-LABEL TIOTROPIUM 2.5 µg RESPIMAT® IN PATIENTS WITH ASTHMA UNCONTROLLED ON HIGH DOSES OF INHALED CORTICOSTEROIDS IN COMBINATION WITH LONG-ACTING ß2-AGONISTS
Actual Study Start Date : April 6, 2016
Actual Primary Completion Date : May 28, 2018
Actual Study Completion Date : May 28, 2018

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Asthma

Arm Intervention/treatment
Experimental: CHF 5993 200/6/12.5 µg

Treatment A:

CHF 5993 200/6/12.5 µg: 2 inhalations bid Total daily dose: 800/24/50 µg BDP/FF/GB

Drug: CHF 5993 200/6/12.5 µg
Active Comparator: CHF 1535 200/6 µg

Treatment B:

CHF 1535 200/6 µg: 2 inhalations bid Total daily dose: 800/24 µg BDP/FF

Drug: CHF 1535 200/6 µg
Active Comparator: CHF 1535 200/6 µg + Tiotropium Respimat 2.5 µg

Treatment C (open-label arm):

CHF 1535 200/6 µg: 2 inhalations bid

+ Tiotropium Respimat 2.5 µg: 2 inhalations od Total daily dose: 800/24 µg BDP/FF + 5 µg Tio

Drug: CHF 1535 200/6 µg + Tiotropium Respimat 2.5 µg



Primary Outcome Measures :
  1. Pre-dose FEV1 (Forced Expiratory Volume in the first second) [ Time Frame: Week 26 ]
  2. Reduction of moderate and severe asthma exacerbations rate [ Time Frame: Week 0 to Week 52 ]

Secondary Outcome Measures :
  1. Peak FEV1 (Peak of Forced Expiratory Volume in the first second) within 3 hours post-dose [ Time Frame: Week 26 ]
  2. Change from baseline in morning PEF (Peak Expiratory Flow) [ Time Frame: Week 0 to Week 26 ]
  3. Reduction of severe asthma exacerbations rate [ Time Frame: Week 0 to week 52 ]
    Pooled analysis of CCD-05993AB1-03 and CCD-05993AB2-02 trials


Other Outcome Measures:
  1. Adverse Events and Adverse Drug reactions [ Time Frame: Up to Week 52 ]
  2. Collection of Health Economics outcomes [ Time Frame: Week 0 to Week 52 ]
    Total use of healthcare resources and absence from work



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years to 75 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • History of asthma ≥ 1 year and diagnosed before 40 years old
  • Uncontrolled asthma with double therapy only on high doses of Inhaled CorticoSteroid (ICS) in combination with Long-Acting Beta2 Agonist (LABA) with ACQ-7 (Asthma Control Questionnaire) ≥1.5
  • Pre-bronchodilator FEV1 <80% of the predicted normal value
  • Positive reversibility test
  • At least 1 documented asthma exacerbation in the previous year

Exclusion Criteria:

  • Pregnant or lactating women
  • Diagnosis of Chronic Obstructive Pulmonary Disease (COPD)
  • Patients with any asthma exacerbation or respiratory tract infection in the 4 weeks prior screening
  • Current smoker or ex-smoker (>= 10 packs year)
  • Any change in dose, schedule or formulation of ICS + LABA combination in the 4 weeks prior screening

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02676089


  Hide Study Locations
Locations
Layout table for location information
Argentina
Chiesi Clinical Trial Site 432704
Caba, Argentina
Chiesi Clinical Trial Site 432702
Ciudad Autónoma de Buenos Aires, Argentina
Chiesi Clinical Trial Site 432705
Mar Del Plata, Argentina
Chiesi Clinical Trial Site 432701
Quilmes, Argentina
Chiesi Clinical Trial Site 432703
San Miguel de Tucumán, Argentina
Chiesi Clinical Trial Site 432706
Tucuman, Argentina
Belarus
Chiesi Clinical Trial Site 112703
Gomel, Belarus
Chiesi Clinical Trial Site 112704
Gomel, Belarus
Chiesi Clinical Trial Site 112701
Minsk, Belarus
Chiesi Clinical Trial Site 112702
Minsk, Belarus
Chiesi Clinical Trial Site 112705
Minsk, Belarus
Bulgaria
Chiesi Clinical Trial Site 100707
Blagoevgrad, Bulgaria
Chiesi Clinical Trial Site 100720
Burgas, Bulgaria
Chiesi Clinical Trial Site 100718
Gabrovo, Bulgaria
Chiesi Clinical Trial Site 100713
Haskovo, Bulgaria
Chiesi Clinical Trial Site 100722
Montana, Bulgaria
Chiesi Clinical Trial Site 100702
Pleven, Bulgaria
Chiesi Clinical Trial Site 100705
Plovdiv, Bulgaria
Chiesi Clinical Trial Site 100708
Plovdiv, Bulgaria
Chiesi Clinical Trial Site 100715
Plovdiv, Bulgaria
Chiesi Clinical Trial Site 100716
Ruse, Bulgaria
Chiesi Clinical Trial Site 100701
Sofia, Bulgaria
Chiesi Clinical Trial Site 100703
Sofia, Bulgaria
Chiesi Clinical Trial Site 100704
Sofia, Bulgaria
Chiesi Clinical Trial Site 100709
Sofia, Bulgaria
Chiesi Clinical Trial Site 100719
Sofia, Bulgaria
Chiesi Clinical Trial Site 100706
Stara Zagora, Bulgaria
Chiesi Clinical Trial Site 100712
Stara Zagora, Bulgaria
Chiesi Clinical Trial Site 100710
Varna, Bulgaria
Chiesi Clinical Trial Site 100711
Vidin, Bulgaria
Chiesi Clinical Trial Site 100721
Vidin, Bulgaria
Czechia
Chiesi Clinical Trial Site 203711
Blansko, Czechia
Chiesi Clinical Trial Site 203702
Brandýs Nad Labem, Czechia
Chiesi Clinical Trial Site 203708
Brno, Czechia
Chiesi Clinical Trial Site 203707
Jindřichův Hradec, Czechia
Chiesi Clinical Trial Site 203705
Kralupy Nad Vltavou, Czechia
Chiesi Clinical Trial Site 203709
Moravský Krumlov, Czechia
Chiesi Clinical Trial Site 203704
Opava, Czechia
Chiesi Clinical Trial Site 203701
Praha, Czechia
Chiesi Clinical Trial Site 203703
Praha, Czechia
Chiesi Clinical Trial Site 203710
Praha, Czechia
Chiesi Clinical Trial Site 203713
Rokycany, Czechia
Chiesi Clinical Trial Site 203706
Teplice, Czechia
Chiesi Clinical Trial Site 203712
Varnsdorf, Czechia
Germany
Chiesi Clinical Trial Site 276709
Berlin, Germany
Chiesi Clinical Trial Site 276712
Berlin, Germany
Chiesi Clinical Trial Site 276711
Bonn, Germany
Chiesi Clinical Trial Site 276707
Frankfurt am Main, Germany
Chiesi Clinical Trial Site 276714
Frankfurt am Main, Germany
Chiesi Clinical Trial Site 276705
Hamburg, Germany
Chiesi Clinical Trial Site 276703
Hannover, Germany
Chiesi Clinical Trial Site 276708
Koblenz, Germany
Chiesi Clinical Trial Site 276702
Leipzig, Germany
Chiesi Clinical Trial Site 276704
Leipzig, Germany
Chiesi Clinical Trial Site 276710
Leipzig, Germany
Chiesi Clinical Trial Site 276715
Mainz, Germany
Chiesi Clinical Trial Site 276701
München, Germany
Chiesi Clinical Trial Site 276713
Münster, Germany
Chiesi Clinical Trial Site 276716
Rosenheim, Germany
Hungary
Chiesi Clinical Trial Site 348707
Balassagyarmat, Hungary
Chiesi Clinical Trial Site 348715
Budapest, Hungary
Chiesi Clinical Trial Site 348721
Debrecen, Hungary
Chiesi Clinical Trial Site 348712
Gödöllő, Hungary
Chiesi Clinical Trial Site 348718
Hatvan, Hungary
Chiesi Clinical Trial Site 348717
Komárom, Hungary
Chiesi Clinical Trial Site 348709
Létavértes, Hungary
Chiesi Clinical Trial Site 348703
Monor, Hungary
Chiesi Clinical Trial Site 348719
Mórahalom, Hungary
Chiesi Clinical Trial Site 348704
Nyíregyháza, Hungary
Chiesi Clinical Trial Site 348714
Nyíregyháza, Hungary
Chiesi Clinical Trial Site 348713
Pécs, Hungary
Chiesi Clinical Trial Site 348702
Siófok, Hungary
Chiesi Clinical Trial Site 348706
Szarvas, Hungary
Chiesi Clinical Trial Site 348701
Szeged, Hungary
Chiesi Clinical Trial Site 348705
Szentgotthárd, Hungary
Chiesi Clinical Trial Site 348720
Vecsés, Hungary
Chiesi Clinical Trial Site 348710
Vásárosnamény, Hungary
Chiesi Clinical Trial Site 348708
Érd, Hungary
Italy
Chiesi Clinical Trial Site 380704
Bologna, Italy
Chiesi Clinical Trial Site 380703
Catania, Italy
Chiesi Clinical Trial Site 380701
Genova, Italy
Chiesi Clinical Trial Site 380705
Palermo, Italy
Chiesi Clinical Trial Site 380702
Pavia, Italy
Chiesi Clinical Trial Site 380706
Tradate, Italy
Lithuania
Chiesi Clinical Trial Site 440702
Vilnius, Lithuania
Chiesi Clinical Trial Site 440703
Vilnius, Lithuania
Chiesi Clinical Trial Site 440705
Vilnius, Lithuania
Chiesi Clinical Trial Site 440701
Šiauliai, Lithuania
Poland
Chiesi Clinical Trial Site 616713
Białystok, Poland
Chiesi Clinical Trial Site 616718
Białystok, Poland
Chiesi Clinical Trial Site 616722
Bielsko-Biala, Poland
Chiesi Clinical Trial Site 616702
Bienkówka, Poland
Chiesi Clinical Trial Site 616727
Bydgoszcz, Poland
Chiesi Clinical Trial Site 616701
Gdańsk, Poland
Chiesi Clinical Trial Site 616704
Giżycko, Poland
Chiesi Clinical Trial Site 616716
Grudziądz, Poland
Chiesi Clinical Trial Site 616725
Katowice, Poland
Chiesi Clinical Trial Site 616729
Katowice, Poland
Chiesi Clinical Trial Site 616719
Kraków, Poland
Chiesi Clinical Trial Site 616734
Kraków, Poland
Chiesi Clinical Trial Site 616736
Kraków, Poland
Chiesi Clinical Trial Site 616733
Mrozy, Poland
Chiesi Clinical Trial Site 616717
Ostróda, Poland
Chiesi Clinical Trial Site 616731
Otwock, Poland
Chiesi Clinical Trial Site 616703
Pabianice, Poland
Chiesi Clinical Trial Site 616709
Poznań, Poland
Chiesi Clinical Trial Site 616728
Poznań, Poland
Chiesi Clinical Trial Site 616720
Proszowice, Poland
Chiesi Clinical Trial Site 616723
Rzeszów, Poland
Chiesi Clinical Trial Site 616735
Rzeszów, Poland
Chiesi Clinical Trial Site 616721
Skierniewice, Poland
Chiesi Clinical Trial Site 616732
Strzelce Opolskie, Poland
Chiesi Clinical Trial Site 616710
Tarnów, Poland
Chiesi Clinical Trial Site 616730
Wilkowice, Poland
Chiesi Clinical Trial Site 616705
Wrocław, Poland
Chiesi Clinical Trial Site 616714
Wrocław, Poland
Chiesi Clinical Trial Site 616715
Wrocław, Poland
Chiesi Clinical Trial Site 616707
Łódź, Poland
Chiesi Clinical Trial Site 616708
Łódź, Poland
Chiesi Clinical Trial Site 616711
Łódź, Poland
Chiesi Clinical Trial Site 616726
Łódź, Poland
Chiesi Clinical Trial Site 616712
Świdnik, Poland
Portugal
Chiesi Clinical Trial Site 620704
Aveiro, Portugal
Chiesi Clinical Trial Site 620703
Figueira Da Foz, Portugal
Chiesi Clinical Trial Site 620702
Lisboa, Portugal
Chiesi Clinical Trial Site 620708
Loures, Portugal
Chiesi Clinical Trial Site 620707
Vila Nova De Gaia, Portugal
Romania
Chiesi Clinical Trial Site 642715
Alexandru cel Bun, Romania
Chiesi Clinical Trial Site 642713
Arad, Romania
Chiesi Clinical Trial Site 642722
Bacău, Romania
Chiesi Clinical Trial Site 642717
Bragadiru, Romania
Chiesi Clinical Trial Site 642706
Braşov, Romania
Chiesi Clinical Trial Site 642703
Bucuresti, Romania
Chiesi Clinical Trial Site 642707
Bucuresti, Romania
Chiesi Clinical Trial Site 642708
Bucuresti, Romania
Chiesi Clinical Trial Site 642719
Bucuresti, Romania
Chiesi Clinical Trial Site 642723
Bucuresti, Romania
Chiesi Clinical Trial Site 642709
Cluj-Napoca, Romania
Chiesi Clinical Trial Site 642714
Cluj-Napoca, Romania
Chiesi Clinical Trial Site 642716
Cluj-Napoca, Romania
Chiesi Clinical Trial Site 642718
Cluj-Napoca, Romania
Chiesi Clinical Trial Site 642726
Cluj-Napoca, Romania
Chiesi Clinical Trial Site 642712
Craiova, Romania
Chiesi Clinical Trial Site 642704
Iaşi, Romania
Chiesi Clinical Trial Site 642710
Iaşi, Romania
Chiesi Clinical Trial Site 642705
Oradea, Romania
Chiesi Clinical Trial Site 642711
Suceava, Romania
Chiesi Clinical Trial Site 642721
Timişoara, Romania
Russian Federation
Chiesi Clinical Trial Site 643724
Anton, Russian Federation
Chiesi Clinical Trial Site 643727
Chelyabinsk, Russian Federation
Chiesi Clinical Trial Site 643733
Chelyabinsk, Russian Federation
Chiesi Clinical Trial Site 643745
Chelyabinsk, Russian Federation
Chiesi Clinical Trial Site 643754
Izhevsk, Russian Federation
Chiesi Clinical Trial Site 643713
Kazan, Russian Federation
Chiesi Clinical Trial Site 643719
Kazan, Russian Federation
Chiesi Clinical Trial Site 643741
Kazan, Russian Federation
Chiesi Clinical Trial Site 643746
Kazan, Russian Federation
Chiesi Clinical Trial Site 643704
Kemerovo, Russian Federation
Chiesi Clinical Trial Site 643731
Kemerovo, Russian Federation
Chiesi Clinical Trial Site 643702
Moscow, Russian Federation
Chiesi Clinical Trial Site 643705
Moscow, Russian Federation
Chiesi Clinical Trial Site 643706
Moscow, Russian Federation
Chiesi Clinical Trial Site 643718
Moscow, Russian Federation
Chiesi Clinical Trial Site 643722
Moscow, Russian Federation
Chiesi Clinical Trial Site 643735
Moscow, Russian Federation
Chiesi Clinical Trial Site 643743
Moscow, Russian Federation
Chiesi Clinical Trial Site 643707
Nizhny Novgorod, Russian Federation
Chiesi Clinical Trial Site 643723
Nizhny Novgorod, Russian Federation
Chiesi Clinical Trial Site 643744
Nizhny Novgorod, Russian Federation
Chiesi Clinical Trial Site 643717
Novosibirsk, Russian Federation
Chiesi Clinical Trial Site 643729
Orenburg, Russian Federation
Chiesi Clinical Trial Site 643711
Pyatigorsk, Russian Federation
Chiesi Clinical Trial Site 643701
Ryazan, Russian Federation
Chiesi Clinical Trial Site 643712
Saint Petersburg, Russian Federation
Chiesi Clinical Trial Site 643714
Saint Petersburg, Russian Federation
Chiesi Clinical Trial Site 643715
Saint Petersburg, Russian Federation
Chiesi Clinical Trial Site 643716
Saint Petersburg, Russian Federation
Chiesi Clinical Trial Site 643725
Saint Petersburg, Russian Federation
Chiesi Clinical Trial Site 643730
Saint Petersburg, Russian Federation
Chiesi Clinical Trial Site 643732
Saint Petersburg, Russian Federation
Chiesi Clinical Trial Site 643737
Saint Petersburg, Russian Federation
Chiesi Clinical Trial Site 643739
Saint Petersburg, Russian Federation
Chiesi Clinical Trial Site 643752
Saint Petersburg, Russian Federation
Chiesi Clinical Trial Site 643757
Saint Petersburg, Russian Federation
Chiesi Clinical Trial Site 643758
Saint Petersburg, Russian Federation
Chiesi Clinical Trial Site 643703
Saratov, Russian Federation
Chiesi Clinical Trial Site 643736
Saratov, Russian Federation
Chiesi Clinical Trial Site 643726
Smolensk, Russian Federation
Chiesi Clinical Trial Site 643740
Stavropol', Russian Federation
Chiesi Clinical Trial Site 643709
Tomsk, Russian Federation
Chiesi Clinical Trial Site 643728
Tomsk, Russian Federation
Chiesi Clinical Trial Site 643759
Tomsk, Russian Federation
Chiesi Clinical Trial Site 643755
Ufa, Russian Federation
Chiesi Clinical Trial Site 643708
Vladikavkaz, Russian Federation
Chiesi Clinical Trial Site 643738
Vladimir, Russian Federation
Chiesi Clinical Trial Site 643710
Voronezh, Russian Federation
Chiesi Clinical Trial Site 643720
Yaroslavl, Russian Federation
Chiesi Clinical Trial Site 643734
Yaroslavl, Russian Federation
Chiesi Clinical Trial Site 643742
Yaroslavl, Russian Federation
Chiesi Clinical Trial Site 643749
Yaroslavl, Russian Federation
Chiesi Clinical Trial Site 643721
Yekaterinburg, Russian Federation
Slovakia
Chiesi Clinical Trial Site 703704
Bratislava, Slovakia
Chiesi Clinical Trial Site 703707
Bratislava, Slovakia
Chiesi Clinical Trial Site 703702
Ilava, Slovakia
Chiesi Clinical Trial Site 703705
Košice, Slovakia
Chiesi Clinical Trial Site 703706
Košice, Slovakia
Chiesi Clinical Trial Site 703701
Nove Zamky, Slovakia
Chiesi Clinical Trial Site 703709
Prievidza, Slovakia
Chiesi Clinical Trial Site 703703
Spišská Nová Ves, Slovakia
Chiesi Clinical Trial Site 703708
Štúrovo, Slovakia
Spain
Chiesi Clinical Trial Site 724703
Badajoz, Spain
Chiesi Clinical Trial Site 724706
Badalona, Spain
Chiesi Clinical Trial Site 724702
Coruña, Spain
Chiesi Clinical Trial Site 724701
Madrid, Spain
Chiesi Clinical Trial Site 724704
Madrid, Spain
Chiesi Clinical Trial Site 724705
Málaga, Spain
Chiesi Clinical Trial Site 724707
Sabadell, Spain
Turkey
Chiesi Clinical Trial Site 792701
Ankara, Turkey
Chiesi Clinical Trial Site 792702
Ankara, Turkey
Chiesi Clinical Trial Site 792703
Antalya, Turkey
Chiesi Clinical Trial Site 792710
Aydın, Turkey
Chiesi Clinical Trial Site 792707
Istanbul, Turkey
Chiesi Clinical Trial Site 792706
Kocaeli, Turkey
Chiesi Clinical Trial Site 792705
Maltepe, Turkey
Chiesi Clinical Trial Site 792708
Mersin, Turkey
Chiesi Clinical Trial Site 792709
Yenişehir, Turkey
Ukraine
Chiesi Clinical Trial Site 804701
Dnipropetrovs'k, Ukraine
Chiesi Clinical Trial Site 804711
Ivano-Frankivs'k, Ukraine
Chiesi Clinical Trial Site 804709
Kharkiv, Ukraine
Chiesi Clinical Trial Site 804710
Kherson, Ukraine
Chiesi Clinical Trial Site 804713
Kiev, Ukraine
Chiesi Clinical Trial Site 804705
Kyiv, Ukraine
Chiesi Clinical Trial Site 804712
Lviv, Ukraine
Chiesi Clinical Trial Site 804715
Sumy, Ukraine
Chiesi Clinical Trial Site 804703
Vinnytsya, Ukraine
Chiesi Clinical Trial Site 804706
Vinnytsya, Ukraine
Chiesi Clinical Trial Site 804707
Vinnytsya, Ukraine
Chiesi Clinical Trial Site 804714
Vinnytsya, Ukraine
Chiesi Clinical Trial Site 804704
Zaporizhzhya, Ukraine
Chiesi Clinical Trial Site 804708
Zhytomyr, Ukraine
United Kingdom
Chiesi Clinical Trial Site 826702
Llanelli, United Kingdom
Chiesi Clinical Trial Site 826703
London, United Kingdom
Chiesi Clinical Trial Site 826704
Manchester, United Kingdom
Chiesi Clinical Trial Site 826701
Soham, United Kingdom
Sponsors and Collaborators
Chiesi Farmaceutici S.p.A.
Investigators
Layout table for investigator information
Principal Investigator: Georgio Walter Canonica, MD University of Medicine, Genoa, Italy

Layout table for additonal information
Responsible Party: Chiesi Farmaceutici S.p.A.
ClinicalTrials.gov Identifier: NCT02676089     History of Changes
Other Study ID Numbers: CCD-05993AB2-02
2015-000717-40 ( EudraCT Number )
First Posted: February 8, 2016    Key Record Dates
Last Update Posted: July 18, 2018
Last Verified: July 2018

Keywords provided by Chiesi Farmaceutici S.p.A.:
Asthma, Anticholinergics, Triple combination

Additional relevant MeSH terms:
Layout table for MeSH terms
Asthma
Bronchial Diseases
Respiratory Tract Diseases
Lung Diseases, Obstructive
Lung Diseases
Respiratory Hypersensitivity
Hypersensitivity, Immediate
Hypersensitivity
Immune System Diseases
Tiotropium Bromide
Formoterol Fumarate
Beclomethasone
Bronchodilator Agents
Autonomic Agents
Peripheral Nervous System Agents
Physiological Effects of Drugs
Anti-Asthmatic Agents
Respiratory System Agents
Parasympatholytics
Cholinergic Antagonists
Cholinergic Agents
Neurotransmitter Agents
Molecular Mechanisms of Pharmacological Action
Adrenergic beta-2 Receptor Agonists
Adrenergic beta-Agonists
Adrenergic Agonists
Adrenergic Agents
Anti-Inflammatory Agents
Glucocorticoids
Hormones